50th week of 2012 patent applcation highlights part 44 |
Patent application number | Title | Published |
20120316057 | OLEFIN METATHESIS CATALYST CONTAINING TUNGSTEN FLUORINE BONDS - A catalyst for the metathesis of olefins in general and specifically for the production of propylene from ethylene and butylene has been developed. The catalyst comprises a tungsten metal compound, which contains at least one tungsten-fluoro bond, dispersed or grafted onto a support. A specific example of the catalyst is the compound WOF(CH | 2012-12-13 |
20120316058 | IONIC LIQUIDS HAVING URONIUM OF THIOURONIUM CATIONS - The present invention relates to salts having thiouronium or uronium cations, to processes for the preparation thereof, and to the use thereof as ionic liquids. | 2012-12-13 |
20120316059 | COMPLEX OXIDE, METHOD FOR PRODUCING SAME AND EXHAUST GAS PURIFYING CATALYST - Disclosed are a silicon-containing cerium composite oxide which is capable of maintaining a large specific surface area even used in a high temperature environment, and which has excellent heat resistance and reducibility, as well as a method for producing the composite oxide and a catalyst for exhaust gas purification employing the composite oxide. The composite oxide contains 2 to 20 mass-% silicon in terms of SiO | 2012-12-13 |
20120316060 | PLATINUM MONOLAYER ON HOLLOW, POROUS NANOPARTICLES WITH HIGH SURFACE AREAS AND METHOD OF MAKING - A catalytic nanoparticle includes a porous, hollow core and an atomically thin layer of platinum atoms on the core. The core is a porous palladium, palladium-M or platinum-M core, where M is selected from the group consisting of gold, iridium, osmium, palladium, rhenium, rhodium and ruthenium. | 2012-12-13 |
20120316061 | FUEL CELL ELECTROCATALYST - This invention provides a highly stable electrocatalyst having excellent electrochemical properties, which comprises a support containing a composite oxide containing Sb-doped SnO | 2012-12-13 |
20120316062 | PESTICIDAL MIXTURES - The present invention relates to synergistic mixtures comprising, as active components, one insecticidal compound I selected from the group of insect growth regulators comprising chitin synthesis inhibitors, moulting disruptors and ecdysone receptor agonists; and one fungicidal compound II selected from the group of strobilurine fungicides in synergistic effective amounts. | 2012-12-13 |
20120316063 | Substituted Quinolinones Having Herbicidal Action - Substituted quinolinones of the formula I | 2012-12-13 |
20120316064 | TREATMENT APPLICATOR - A fluid application apparatus is disclosed having adhesive compositions and controlled release compositions for applying treatments such as pesticides, herbicides, and fertilizers, to target plants, and the like. In at least one embodiment, the application apparatus includes a treatment release device adapted to release a pesticide, herbicide, fertilizer, or the like, for adhesion to and treatment of a target plant, the release device comprising: a substrate; a quantity of media adapted to contain a controlled release composition disposed upon the substrate and adapted to release the controlled release composition to a target plant for treatment; and an adhesive composition disposed upon the substrate and adapted to adhere the treatment release device and the quantity of media adapted to contain a controlled release composition to the target plant for treatment. | 2012-12-13 |
20120316065 | SURFACTANT BLENDS FOR AUXIN ACTIVITY HERBICIDES - The present invention teaches a surfactant blend composition of at least one alcohol alkoxylate and at least one alkoxylated quaternary, and its use as an adjuvant for auxin-based pesticides. The pesticidal composition employing the surfactant blend composition of the invention realizes an efficacy that is unexpectedly superior to similar pesticidal compositions which employ only the individual surfactant components. The composition of the present invention is useful as a tank side additive, or as a component in the mention pesticidal formulations. | 2012-12-13 |
20120316066 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex - The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements. | 2012-12-13 |
20120316067 | INSECTICIDAL N-SUBSTITUTED (6-HALOOALKYLPYRIDIN-3-YL)-ALKYL SULFOXIMINES - N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects. | 2012-12-13 |
20120316068 | EMULSION ADJUVANT FOR HERBICIDES - An oil-in-water emulsion liquid composition suitable for use as an agricultural adjuvant comprising an oil, a saturated or substantially saturated aqueous solution of an ammonium salt and one or more of high molecular weight polymeric surfactants. | 2012-12-13 |
20120316069 | SUPOERCONDUCTING FAULT CURRENT LIMITER RECOVERY SYSTEM - A superconducting fault current limiter recovery system includes a superconducting fault current limiter, a shunt electrically coupled in parallel with the superconducting fault current limiter, and a bypass path also electrically coupled in parallel with the superconducting fault current limiter. The bypass path enables a load current to flow through the bypass path during a bypass condition. Thus, load current may be quickly reestablished to serve loads after a fault condition via the bypass path while a superconductor of the superconductor fault current limiter has time to return to a superconducting state after the fault condition. | 2012-12-13 |
20120316070 | Superconducting Fault Current Limiter Monitoring - A superconducting fault current limiter (SCFCL) includes a cryogenic tank defining an interior volume, a superconductor disposed in the interior volume, and a voltage detector configured to detect a voltage drop across the superconductor and provide a voltage signal representative of the voltage drop. This voltage detector enables real time monitoring of a condition of the superconductor during steady state operation of the SCFCL. If the voltage drop exceeds an acceptable voltage drop, corrective action such as maintenance, repair, and/or replacement may be taken. | 2012-12-13 |
20120316071 | METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION - Provided herein is a rational method of affinity maturation to evolve the activity of an antibody or portion thereof based on the structure/affinity or activity relationship of an antibody. The resulting affinity matured antibodies exhibit improved or optimized binding affinity for a target antigen. | 2012-12-13 |
20120316072 | Methods for indexing samples and sequencing multiple polynucleotide templates - The invention relates to methods for indexing samples during the sequencing of polynucleotide templates, resulting in the attachment of tags specific to the source of each nucleic acid sample such that after a sequencing run, both the source and sequence of each polynucleotide can be determined. Thus, the present invention pertains to analysis of complex genomes (e.g., human genomes), as well as multiplexing less complex genomes, such as those of bacteria, viruses, mitochondria, and the like. | 2012-12-13 |
20120316073 | STRATEGIES FOR HIGH THROUGHPUT IDENTIFICATION AND DETECTION OF POLYMORPHISMS - The invention relates to a method for the high throughput identification of single nucleotide polymorphisms by performing a complexity reduction on two or more samples to yield two or more libraries, sequencing at least part of the libraries, aligning the identified sequences and determining any putative single nucleotide polymorphisms, confirming any putative single nucleotide polymorphism, generating detection probes for the confirmed single nucleotide polymorphisms, subjection a test sample to the same complexity reduction to provide a test library and screen the test library for the presence or absence of the single nucleotide polymorphisms using the detection probe. | 2012-12-13 |
20120316074 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS - Provided herein are methods, compositions, and kits for assays, many of which involve amplification reactions such as digital PCR or droplet digital PCR. The assays may be used for such applications as sequencing, copy number variation analysis, and others. In some cases, the assays involve subdividing a sample into multiple partitions (e.g., droplets) and merging the partitions with other partitions that comprise adaptors with barcodes. | 2012-12-13 |
20120316075 | SEQUENCE PRESERVED DNA CONVERSION FOR OPTICAL NANOPORE SEQUENCING - The present invention relates to a method for conversion of a target nucleic acid molecule according to a predetermined nucleotide code into a converted nucleic acid molecule. The converted nucleic acid molecule has utility for determining the nucleotide sequence of the target nucleic acid molecule, for example, using a nanopore. | 2012-12-13 |
20120316076 | BIOMARKERS FOR THE DIAGNOSIS OF LACUNAR STROKE - This invention provides gene expression profiles useful for diagnosing lacunar stroke and for distinguishing lacunar stroke from non-lacunar stroke. | 2012-12-13 |
20120316077 | System And Method For Detection And Analysis Of A Molecule In A Sample - Disclosed here is a system and method for analyzing and/or detecting one or more target analytes in a sample by using a competitive assay. A standard curve may be constructed using known amounts of a molecule that is identical or substantially identical to the target analyte. Signals obtained from the target analyte can be compared against the standard curve in order to determine the level of the target analyte in the sample. The disclosed methods may be used in a multiplexed analyte detection and quantitation system. | 2012-12-13 |
20120316078 | METHODS AND MATERIALS FOR PRODUCING POLYPEPTIDES IN VITRO - Methods for producing polypeptides in vitro are described that use free template nucleic acids that are not immobilized on a substrate. Polypeptides that are produced can be captured on particles without the use of capture agents and can be used to produce polypeptide arrays. | 2012-12-13 |
20120316079 | Low Density Microarrays for Vaccine Related Protein Quanitification, Potency Determination and Efficacy Evaluation - Methods for the quantification of influenza HA proteins and anti-influenza antibodies for the fields of vaccine-related protein quantification, potency determination, and efficacy evaluation are provided. According to the technology, quantification is achieved by providing capture agents attached to an array in a series of decreasing concentrations. Serial dilutions of a reference material also may be introduced. The reference material within each solution binds to the capture agents on the array and is labeled with a label agent capable of producing a detectable signal used to construct a calibration curve. A target material of unknown concentration is introduced to a separate identical array, and the target material binds to the capture agents and also is labeled by a label agent to produce a detectable signal. The calibration curve based on the reference material is then utilized to determine the concentration of the target material without the need to perform replicate experiments. | 2012-12-13 |
20120316080 | DIFFERENTIATION BETWEEN BRCA2-ASSOCIATED TUMOURS AND SPORADIC TUMOURS VIA ARRAY COMPARATIVE GENOMIC HYBRIDIZATION - Array comparative genomic hybridization classifiers, arrays comprising the classifiers and methods of using the same for differentiating between BRCA2-associated tumors and sporadic tumors by detecting phenotypic genetic traits using comparative genomic hybridization are disclosed. | 2012-12-13 |
20120316081 | Method of Identifying Myelodysplastic Syndromes - Myelodysplastic syndromes display both hematological and biological heterogeneity with variable leukemia potential. To determine whether microRNAs expression offers diagnostic discrimination or influences malignant potential in MDS, bone marrow miRNA expression was investigated from prognostically distinct MDS subsets using a microarray platform. After background subtraction and normalization, data were analyzed indicating thirteen miRNA signature with statistically significant differential expression, including down-regulation of members of a leukemia associated miRNA family. A unique signature consisting of 10 miRNAs was closely associated with International Prognostic Scoring System risk category permitting discrimination between lower and higher risk disease. Selective overexpression of miRNA-181 family members was detected in higher risk MDS, indicating pathogenetic overlap with acute myeloid leukemia. Analysis of miRNA expression profile offers diagnostic utility, and provides pathogenetic and prognostic discimination in MDS. | 2012-12-13 |
20120316082 | NUCLEIC ACID DETECTION AND QUANTIFICATION BY POST-HYBRIDIZATION LABELING AND UNIVERSAL ENCODING - The present invention provides, among other things, methods and compositions for detecting and quantifying target nucleic acids via post-hybridization labeling. | 2012-12-13 |
20120316083 | Methods of Detecting Target Nucleic Acids - The present disclosure relates to methods of identifying target nucleic acids by using coded molecules and its analysis by translocation through a nanopore. Generally, coded molecules are subject to a target polynucleotide dependent modification. The modified coded molecule is detected by isolating the modified coded molecules from the unmodified coded molecules prior to analysis through the nanopore or by detecting a change in the signal pattern of the coded molecule when analyzed through the nanopore. | 2012-12-13 |
20120316084 | GENE EXPRESSION PROFILING FROM FFPE SAMPLES - Methods and compositions relating to the generation and use of gene expression data from tissue samples that have been fixed and embedded are provided. The data can electronically stored and implemented as well as used to augment diagnosis and treatment of diseases. | 2012-12-13 |
20120316085 | ANTIBODY HUMANIZATION BY FRAMEWORK ASSEMBLY - An improved method for producing humanized antibody or an antigen binding fragment thereof is described. The method, designated framework-assembly, bypasses the reliance on structural biology and the construction of large libraries. It is easier to implement and more efficient than the rational design and empirical methods. Also described are humanized antibodies produced by the method and related framework-assembly library. | 2012-12-13 |
20120316086 | PATTERNED FLOW-CELLS USEFUL FOR NUCLEIC ACID ANALYSIS - Provided is a surface having metal regions and an interstitial region having a composition that differs from the metal regions, wherein a continuous gel layer coats the surface across the metal regions and the interstitial regions. Nucleic acids or other analytes can be attached to the continuous gel layer such that a greater amount is attached over the metal regions than over the interstitial region. Also provided are methods for making such surfaces. Methods are also provided for making an array of nucleic acids or other analytes using such surfaces. | 2012-12-13 |
20120316087 | Nucleic Acid Analyzer, Reaction Device for Nucleic Acid Analysis and Substrate of Reaction Device for Nucleic Acid Analysis - Provided is a reaction device for nucleic acid analysis wherein microparticles, which carry a nucleic acid to be detected having been immobilized thereon, are aligned in a lattice form on a substrate according to the pixel size of a two-dimensional sensor. By this reaction device for nucleic acid analysis which is provided with a channel-forming reaction chamber on the substrate ( | 2012-12-13 |
20120316088 | Method to Characterize Fracture Plugging Efficiency for Drilling Fluids - A method for determining a Plug Normal Stress Difference (ΔN | 2012-12-13 |
20120316089 | Methods to Characterize Fracture Plugging Efficiency for Drilling Fluids - A drilling fluid may include a base drilling fluid and a plurality of particulates, wherein a concentration of the particulates in the base drilling fluid provides for ΔN | 2012-12-13 |
20120316090 | ENVIRONMENTALLY FRIENDLY DISPERSION SYSTEM USED IN THE PREPARATION OF INVERSE EMULSION POLYMERS - A water-in-oil emulsion composition and method of production is disclosed. The composition may comprise a monomer phase, an organic phase, at least one initiator, and an inverting phase. The monomer phase may further comprise at least one monomer, water, ammonium chloride, sodium 2-acrylamido-2-methyl-1-propanesulfonate, tetrasodium ethylenediaminetetraacetate, and at least one water soluble ethylenically unsaturated monomer. The organic phase may further comprise at least one hydrophobic solvent, lecithin, and a polyoxyethylene derivative of a sorbitan ester. The at least one monomer may be selected from the group consisting of an acrylic monomer, an acrylamide monomer, and combinations thereof. | 2012-12-13 |
20120316091 | THICKENER, GREASE, METHOD FOR PRODUCING THE SAME,AND GREASE-PACKED BEARING - The present invention provides a thickener which allows grease having an excellent durability in a high-temperature and high-speed condition to be produced, the grease containing the thickener, a method of producing the thickener and the grease, and a grease-packed bearing. A grease ( | 2012-12-13 |
20120316092 | LUBRICANT COMPOSITION FOR CONTINUOUSLY VARIABLE TRANSMISSION - A lubricating oil composition for a continuously variable transmission contains at a specific content: (A) a mineral oil or PAO having a sulfur content of 0.03 mass % or less and a kinematic viscosity at 100 degrees C. from 1.5 mm | 2012-12-13 |
20120316093 | CONVERSION OF FATTY ACIDS TO BASE OILS AND TRANSPORTATION FUELS - The present invention is directed to methods for processing fatty acids to provide for base oil and transportation fuels, wherein decarboxylation-coupling dimerization of fatty acids provides dimer ketones from which the base oils and transportation fuels may be produced. | 2012-12-13 |
20120316094 | GEAR OIL COMPOSITIONS - A novel lubricant composition is disclosed. In one embodiment the lubricant composition comprises in admixture: a first base stock component comprising one or more base stocks each having a viscosity of at least 40 cSt, Kv100° C. and a molecular weight distribution (MWD) as a function of viscosity at least 10 percent less than algorithm: MWD=0.2223+1.0232*log (Kv at 100° C. in cSt); and a second base stock component comprising one or more base stocks each having a viscosity less than 10 cSt, Kv100° C. | 2012-12-13 |
20120316095 | Personal Care Compositions - A personal care composition includes a cleansing phase and a benefit phase. The cleansing phase includes a surfactant and the benefit phase includes a benefit agent, where the benefit agent comprises a sucrose polyester with an iodine value of 3 or more. | 2012-12-13 |
20120316096 | PAINT STRIPPER - A paint stripper composition includes from about 70 to about 76 percent by volume of methylene chloride, from about 10 to about 14 percent by volume of isopropanol, from about 5 to about 8 percent by volume of formic acid, from about 1.5 to about 2.5 percent by volume of OP-10, from about 1 to about 2.5 percent by volume of phenol, and from about 2 to about 4 percent by volume of ozocerite, based upon 100 percent by volume of the total composition. | 2012-12-13 |
20120316097 | DETERGENT FOR METAL - A detergent composition for metal according to the present invention contains a specific non-ionic surfactant, a specific nitrogen-containing organic compound, a specific carboxylic acid or salt thereof, and a specific alkanol amine, and has a pH of at least 9 that is measured at 25° C. when the detergent composition is diluted to 1% by mass of an aqueous solution. According to the present invention, the detergent composition for metal having excellent corrosion inhibition properties, excellent effluent treatment properties, excellent foaming suppressing properties and excellent liquid stability in addition to high detergent properties for metal, can be provided. | 2012-12-13 |
20120316098 | METHOD OF PRODUCING A FABRIC SOFTENING COMPOSITION - The present invention is to process of making a liquid fabric softening composition using shear, turbulence and/or cavitation, but which requires lower operating pressures than conventional shear, turbulence and/or cavitation processes. | 2012-12-13 |
20120316099 | COMPOSITIONS COMPRISING SUPERHYDROPHILIC AMPHIPHILIC COPOLYMERS AND METHODS OF USE THEREOF - Provided are compositions comprising a superhydrophilic amphiphilic copolymer and a carrier and composition comprising a superhydrophilic amphiphilic copolymer, a micellar thickener and a carrier. | 2012-12-13 |
20120316100 | Therapeutic Use of Peptide Inhibitors of NADPH Oxidase; Aerosolization as a Delivery Mechanism - A method is provided for treatment of a condition mediated by Nox2 in a patient. The method comprises administering to the patient by inhalation a polypeptide as described herein, able to inhibit superoxide production by Nox2. Conditions treatable in this manner include, without limitation, one or more of: right ventricular hypertrophy; pulmonary hypertension; acute lung injury; obstructive sleep apnea; ischemia/reperfusion injury in the lung; pulmonary fibrosis; an obstructive lung disorder such as Chronic Obstructive Pulmonary Disease (COPD), asthma, cystic fibrosis and emphysema; and atherosclerosis | 2012-12-13 |
20120316101 | PEPTIDES FOR TARGETING APOPTOTIC CELLS AND USES THEREOF - The present invention relates to a polypeptide capable of specifically targeting apoptotic cells undergoing apoptosis and a use thereof. More particularly, it relates to an isolated polypeptide consisting of the sequence (I): Cys-X1-Val-Ala-Pro-X2 (I), wherein X1 is an amino acid with polar uncharged side chain and X2 is an amino acid with positive charged side chain and targeting apoptotic cells, a composition for detection of apoptotic cells comprising the same as an effective ingredient, a composition for drug delivery comprising the same as an effective ingredient, a composition for imaging comprising the same as an effective ingredient and the like. Accordingly, the peptide of the present invention may be useful for detection of apoptotic cells, as well as detection and imaging of apoptotic cells in tumor tissue, apoptotic myocardial cells in myocardial infarction tissue, apoptotic nerve cells in stroke tissue and arteriosclerosis site, and targeted drug delivery thereto. | 2012-12-13 |
20120316102 | ANTIMICROBIAL PEPTIDES OF THE CECROPIN FAMILY AND THERAPEUTIC USES THEREOF - The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections. | 2012-12-13 |
20120316103 | CYCLIC ANTIMICROBIAL PEPTIDES - The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections. | 2012-12-13 |
20120316104 | USE OF BACTERIOPHAGE OUTER MEMBRANE BREACHING PROTEINS EXPRESSED IN PLANTS FOR THE CONTROL OF GRAM-NEGATIVE BACTERIA - The present invention provides compositions and methods for killing or suppressing growth of Gram-negative bacteria that infect, infest or cause disease in plants, including pathogenic, saprophytic and opportunistic microbes that cause disease in plants and food borne illness in people or in animal feed. | 2012-12-13 |
20120316105 | Polymyxin Derivates Useful As Antibacterial Agents - The present invention provides a new class of polymyxin derivates useful for treating bacterial infections, especially Gram-negative infections, that have reduced renal cytotoxicity. | 2012-12-13 |
20120316106 | SYNERGISTIC ANTIBIOTIC COMBINATIONS AND DERIVATIVES - Improved antibiotic analogs, and synergistic combinations of antibiotics designed based on structural crystallographic analysis, are provided as well as pharmaceutical compositions that include these improved analogs and synergistic combinations, along with methods for their production and use. The synergistic combinations target neighboring sites in the ribosome demonstrating the importance of the corresponding ribosomal sites for development of clinically-relevant synergistic antibiotics. | 2012-12-13 |
20120316107 | FIBRILLATION-RESISTANT INSULIN AND INSULIN ANALOGUES - A fibrillation-resistant insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A chain sequence or an analogue thereof and an insulin B chain sequence or an analogue thereof connected by a polypeptide of 4-10 amino acids. The fibrillation-resistant insulin analogue preferably displays less than 1 percent fibrillation with incubation at 37° C. for at least 21 days. A single-chain insulin analogue displays greater in vitro insulin receptor binding than normal insulin while displaying less than or equal binding to IGFR than normal insulin. The fibrillation-resistant insulin may be used to treat a patient using an implantable or external insulin pump, due to its greater fibrillation resistance. | 2012-12-13 |
20120316108 | PHOSPHOLIPID DEPOT - The present invention is directed to compositions and methods of preparation of phospholipid depots that are injectable through a fine needle. | 2012-12-13 |
20120316109 | POLYMER-CONJUGATED GLYCOSYLATED NEUBLASTIN - The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin. | 2012-12-13 |
20120316110 | Injectable Cross-Linked Polymeric Preparations and Uses Thereof - A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue. | 2012-12-13 |
20120316111 | BMP-2 Upregulating Compounds For Healing Bone Tissue And Screening Methods For Selecting Such Compounds - The present disclosure relates to a method to stimulate endogenous BMP-2 up-regulation in a subject which method comprises administering to a subject an effective amount of one or more of the following compounds prazosin, quinacrine, emetine, apomorphine, and debrisoquine, whereby endogenous BMP-2 up-regulation is stimulated in said subject. The endogenous BMP-2 up-regulation may enhance bone formation and/or cartilage formation. | 2012-12-13 |
20120316112 | RESCUE OF PHOTORECEPTORS BY INTRAVITREAL ADMINISTRATION OF AN EXPRESSION VECTOR ENCODING A THERAPEUTIC PROTEIN - The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells. | 2012-12-13 |
20120316113 | FGF BASED FIBRIN BINDING PEPTIDES - The present invention relates to a polypeptide fragments of Fibroblast Growth Factor 2, wherein said fragments are adapted to bind to fibrinogen or to fibrin and/or increase cell proliferation, differentiation or migration. These fragments are suitable for promoting wound healing and/or hemostasis. | 2012-12-13 |
20120316114 | Variants of C-type Natriuretic Peptide - The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis). | 2012-12-13 |
20120316115 | METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS - The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease. | 2012-12-13 |
20120316116 | TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF - The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII. | 2012-12-13 |
20120316117 | PROCESS TO PRODUCE FIBRILLAR PROTEINS AND METHOD OF TREATMENT USING FIBRILLAR PROTEINS - A method for inhibiting survival of cancer cells in a subject is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of fibrillar albumin. The preparation of the fibrillar albumin comprises: (i) forming a solution comprising an isolated and/or purified globular albumin; (ii) adding a detergent to the solution containing the isolated and/or purified globular albumin, wherein the detergent is one selected from the group consisting of sodium dodecyl sulfate (SDS) and n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate; (iii) applying the solution to a molecular sizing column with a pore size that permits separation of a protein with a molecular weight of at least about 70 kDa so as to promote column-induced formation of the fibrillar albumin from the isolated and/or purified globular albumin; and (iv) eluting the fibrillar albumin from the column, wherein the eluted albumin has a fibrillar structure. | 2012-12-13 |
20120316118 | OLIGOPEPTIDE IMPROVING DIFFERENTIATION OF OSTEOBLASTS - The present disclosure relates to oligopeptides applicable to a dental implant, which are selected from the group consisting of PEP7 (SEQ ID NO:1), PEP71 (SEQ ID NO:2), EP72 (SEQ ID NO:3), PEP73 (SEQ ID NO:4), PEP74 (SEQ ID NO:5), PEP75 (SEQ ID NO:6) and PEP76 (SEQ ID NO:7). The oligopeptides have very high reactivity for a BMP-specific receptor to increase osteoblastic differentiation and calcification, thereby showing improved osteointegration and osteogenesis. | 2012-12-13 |
20120316119 | PEPTIDE COMPOSITION FOR CANCER TREATMENT BY INHIBITING TRPV6 CALCIUM CHANNEL ACTIVITY - The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer. | 2012-12-13 |
20120316120 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF - Fluorinated compounds and methods of making fluorinated compounds are described herein. | 2012-12-13 |
20120316121 | Materials and Methods for Modulating Arginine Metabolism - The present invention provides novel compositions and methods for their production and use in modulating arginine metabolism to treat biological conditions. The biological condition is preferably one associated with dysregulated arginine metabolism and/or abnormal endogenous levels of substances resulting from or involved in arginine metabolism. The subject invention provides compositions that modulate levels of arginine or levels of substances that are derived from arginine in vivo via pre-selected signal transduction/metabolic pathways. In one embodiment, compositions comprising arginine and a glycoside are provided. The compositions and methods of the invention are able to select and prompt a particular metabolic pathway in which the arginine is to be used as a substrate. | 2012-12-13 |
20120316122 | PHARMACEUTICAL COMPOSITIONS FOR COMBATING THROMBOTIC DISEASES AND THEIR PREPARATION AND USES - The present invention relates to a pharmaceutical composition for combating a thrombotic disease and a method for making the same and a use thereof. The pharmaceutical composition mainly comprises timosaponin AIII and timosaponin BII, and optionally pharmaceutically acceptable excipients, characterized in that the amount of timosaponin AIII is greater than or equal to the amount of timosaponin BII. The present invention further relates to a use of timosaponin AIII and timosaponin BII in manufacturing a medicament or product for the prophylaxis or to treatment of a thrombotic disease. The present pharmaceutical composition can not only bring about effects of prophylaxis or treatment of a thrombotic disease, but also alleviate blood bleeding or bleeding tendency in patients. | 2012-12-13 |
20120316123 | DIETARY SUPPLEMENT COMPOSITION OF CITRUS DERIVATIVES - There is disclosed a dietary supplement composition of alkaloids and flavonoids extracted from citrus fruits that exhibits lipolytic and thermogenic activity and increases RMR, while at the same time exhibiting no negative side effects such as increase in blood pressure or heart rate. The composition essentially comprises two components: (A) the protoalkaloids synephrine, tyramine, N-methyltyramine, hordenine and octopamine; and (B) at least one of hesperidin, naringin and mixtures thereof. | 2012-12-13 |
20120316124 | ISOXAZOLINE DERIVATIVES AS INSECTICIDES - The present invention relates to compounds formula (I), wherein P is P1, P2, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A | 2012-12-13 |
20120316125 | AMINOGLYCOSIDES: SYNTHESIS AND USE AS ANTIFUNGALS - The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present invention are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease. | 2012-12-13 |
20120316126 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2012-12-13 |
20120316127 | METHOD OF MANUFACTURING COATING AGENT FOR DRUG RELEASING STENT AND COATING AGENT FOR DRUG RELEASING STENT MANUFACTURED THEREBY - This invention relates to a method of manufacturing a coating agent for a drug releasing stent and to a coating agent for a drug releasing stent manufactured thereby. This method includes (1) dissolving polyurethane in tetrahydrofuran, (2) dissolving pluronic F-127 in tetrahydrofuran, (3) dissolving a gemcitabine compound in ethanol, (4) mixing these three solutions obtained in (1) to (3) thus preparing a solution mixture, (5) applying the solution mixture obtained in (4) on a stent coated with a Teflon film, (6) drying the stent of (5) for a predetermined period of time and then immersing the stent in a polyurethane solution in tetrahydrofuran, and (7) removing the stent immersed in (6) from the polyurethane solution and then drying the stent, so that the rate of release of an anti-cancer drug applied on the stent can be continuously and maximally improved thereby maximizing anti-cancer efficacy. | 2012-12-13 |
20120316128 | CITICOLINE FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION - The present invention refers to citicoline and to compositions containing it for topic use in treating glaucoma and/or ocular hypertension. | 2012-12-13 |
20120316129 | LIQUID DRESSING CONTAINING CHITOSAN DERIVATIVE AND PREPARATION METHOD THEREOF - The invention relates to a liquid dressing containing a chitosan derivative, comprising the following components in percentage by weight: 1-5% of CMCS (carboxymethyl chitosan), 0.1-0.5% of collagen albumen powder, 10-15% of humectant, 0.2-2% of antibacterial agent, 2-10% of penetration enhancers and the balance of deionized water. The liquid dressing is obtained by mixing the components in sequence, stirring evenly and bulking. The liquid dressing has the advantage of good biocompatibility, good antimicrobial, antiphlogistic and hemostatic effects and high biological safety, and is convenient to use. | 2012-12-13 |
20120316130 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-DEPENDENT DISEASES AND CONDITIONS - A pharmaceutical composition for the treatment of an estrogen-dependent disease or condition comprises: (1) at least one polysaccharide selected from the group consisting of an alginate and a fucoidan in a quantity effective to treat an estrogen-dependent disease or condition; and (2) a pharmaceutically acceptable carrier. The composition can include both an alginate and a fucoidan. The composition can include other ingredients such as at least one compound selected from the group consisting of diindolylmethane and indole-3-carbinol in a quantity sufficient to inhibit the activity of estrogen. Methods for use of the composition for the treatment of an estrogen-dependent disease or condition, especially endometriosis, are described. | 2012-12-13 |
20120316131 | Stable Hyaluronan/Steroid Formulation - A pharmaceutical composition comprising in admixture a hyaluronic acid related component (HARC) and a pharmaceutically effective amount of triamcinolone hexacetonide (TAH). The composition is stable in an accelerated shelf life test in which the composition is heated to 80° C. for 24 hours. | 2012-12-13 |
20120316132 | PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE - The present invention concerns a pharmaceutical formulation intended for oral administration containing a synthetic oligosaccharides containing one to 18 monosaccharide units and having a therapeutical activity or a pharmaceutically acceptable additions salt or solvate thereof wherein the formulation contains: a) the synthetic oligosaccharide (A) in an amount of up to 5% by weight of the total weight of the formulation, advantageously up to 1% by weight of the total weight of the formulation, b), a lipophilic phase (B) consisting of triglyceride of fatty acids in an amount of 50 to 80% by weight of the total weight of the formulation, advantageously of 50 to 70% by weight of the total weight of the formulation, c) at least one lipophilic surfactant (C) with HLB below 7 consisting of partial esters of polyol and fatty acids in an amount of 10 to 30% by weight of the total weight of the formulation, advantageously of 15 to 30% by weight of the total weight of the formulation, d) at least one hydrophilic surfactant (D) with HLB above 7 in an amount of up to 20% by weight of the total weight of the formulation, advantageously up to 15% by weight of the total weight of the formulation, e) optionally, at least one hydrophilic solvent (E) in an amount of up to 15% by weight of the total weight of the formulation, advantageously up to 10% by weight of the total weight of the formulation, (F) between 0 and 30% by weight of the total weight of the formulation of a chemical and/or physical stabilization agent (F), advantageously between 0 and 20% by weight of the total weight of the formulation, wherein when the formulation is in a form of a reverse emulsion or microemulsion and contains at least one hydrophilic solvent (E), the physical stabilization agent is present and is silicon dioxide. | 2012-12-13 |
20120316133 | AQUEOUS IRON CARBOHYDRATE COMPLEXES, THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM - A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions. | 2012-12-13 |
20120316134 | ANAESTHETIC COMPOSITION - A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a bugger, excluding phosphate buffer pH 7.0, 0.1 M mixed as defined in the British Pharmadopoeia 1998, such that the pH of the solution is from 6.0-8.0. | 2012-12-13 |
20120316135 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers - The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I: | 2012-12-13 |
20120316136 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS - The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof. | 2012-12-13 |
20120316137 | Methods and Compositions for Treating Cancer - The invention features methods, kits, and pharmaceutical compositions for treating cancer using 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)-methyl)-3-(trifluoromethyl)phenyl)benzamide. | 2012-12-13 |
20120316138 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES - The present invention relates to thiazolidinedione analogues and pharmaceutical compositions that are useful for treating and/or preventing obesity or diabetes, optionally in combination with a second treatment therapy such a diet restriction or an increase in duration or exertion in physical activity. | 2012-12-13 |
20120316139 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF - Compounds of the general formula | 2012-12-13 |
20120316140 | ANALGESIC COMPOSITION AND METHOD OF MAKING THE SAME - A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solublizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia. | 2012-12-13 |
20120316141 | METHOD FOR PROVIDING NEUROPROTECTION FROM SPINAL MUSCULAR ATROPHY - A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I | 2012-12-13 |
20120316142 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS - Compounds of formula I | 2012-12-13 |
20120316143 | Ophthalmic composition - It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range. | 2012-12-13 |
20120316144 | ANTIFUNGAL AGENT - An antifungal agent including a mastic normal-hexane extract containing at least one of triterpenes expressed by the following chemical formulas 1 to 6; | 2012-12-13 |
20120316145 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-benzylidene derivatives of the formula I, in which Y and X are each as defined in the claims and the description, | 2012-12-13 |
20120316146 | ANAESTHETIC FORMULATION - The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof. | 2012-12-13 |
20120316147 | NOVEL PYRIDINE DERIVATIVES - The invention relates to a compound of formula (I) | 2012-12-13 |
20120316148 | Compositions and Methods for Modulating a Kinase - The invention relates to compounds and methods for modulating one or more components of a kinase signaling cascade. | 2012-12-13 |
20120316149 | HETEROCYCLIC SULFONAMIDE DERIVATIVES - The present invention relates to compounds: | 2012-12-13 |
20120316150 | AMIDE COMPOUNDS USEFUL IN THERAPY - A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, | 2012-12-13 |
20120316151 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS - This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer. | 2012-12-13 |
20120316152 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES - A method for the treatment or prevention in a mammal of a disease associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase comprising administering to the mammal in need thereof at least one compound of the formula (I) | 2012-12-13 |
20120316153 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to benzazepine derivatives of the formula (I) | 2012-12-13 |
20120316154 | FUSED TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X | 2012-12-13 |
20120316155 | Imidazole-2,4-Dione Inhibitors of Casein Kinase 1 - Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway. | 2012-12-13 |
20120316156 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID - The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a [1,2,4]thiadiazine 1,1-dioxide compound. | 2012-12-13 |